Back to top
more

Microbot Medical (MBOT)

(Delayed Data from NSDQ)

$2.55 USD

2.55
1,495,248

+0.02 (0.79%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $2.56 +0.01 (0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Ryanair, Monster Beverage, Ulta Beauty in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

MBOT Stock Gains Following FDA Submission of the LIBERTY System

by Zacks Equity Research

Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.

Zacks Equity Research

Microbot Medical Stock Rises After Completing ACCESS-PVI Trial

by Zacks Equity Research

MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.

Zacks Equity Research

Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY

by Zacks Equity Research

Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.

Zacks Equity Research

Microbot Medical (MBOT) Gets Quality Certification for its System

by Zacks Equity Research

Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.

Zacks Equity Research

Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics

by Zacks Equity Research

Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.

Zacks Equity Research

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

by Zacks Equity Research

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

Zacks Equity Research

Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial

by Zacks Equity Research

Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.

Zacks Equity Research

Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY

by Zacks Equity Research

Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.

Zacks Equity Research

Microbot Medical (MBOT) Files IDE to Start Human Clinical Study

by Zacks Equity Research

Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.

Zacks Equity Research

Microbot Medical (MBOT) Announces Positive GLP Study Results

by Zacks Equity Research

Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.

Zacks Equity Research

Microbot Medical Inc. (MBOT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Microbot Medical Inc. (MBOT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Company News for Dec 28, 2021

by Zacks Equity Research

Companies in The News Are: GDDY,BBIO,UAL,MBOTSYK

Zacks Equity Research

Microbot Medical Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Microbot Medical.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

Tirthankar Chakraborty headshot

Buy Multibagger Stocks as Odds of a Rally Are High in 2020

by Tirthankar Chakraborty

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.